HOOK (HOOKIPA Pharma) ROC (Joel Greenblatt) %: -1,182.78% (As of Jun. 2025)


HOOK HOOKIPA Pharma Inc HOOK
50 GF Score
Price $1.15
View Full Analysis

What is HOOKIPA Pharma ROC (Joel Greenblatt) %?

HOOKIPA Pharma HOOK 50 ROC (Joel Greenblatt) % is -1,182.78% as of Jun. 2025. GuruFocus rates HOOK with a GF Score™ of 50/100. Among 1,321 Biotechnology companies, HOOKIPA Pharma ranks worse than 69.34% on this metric.

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. HOOKIPA Pharma's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2025 was -1,182.78%.

The historical rank and industry rank for HOOKIPA Pharma's ROC (Joel Greenblatt) % or its related term are showing as below:

HOOK's ROC (Joel Greenblatt) % is not ranked *
in the Biotechnology industry.
Industry Median: -296.6
* Ranked among companies with meaningful ROC (Joel Greenblatt) % only.

HOOKIPA Pharma's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was 0.00% per year.


HOOKIPA Pharma  (OTCPK:HOOK) ROC (Joel Greenblatt) % Explanation

The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.

Joel Greenblatt uses his definition of Return on Capital and Earnings Yield (Joel Greenblatt) % to rank companies.


HOOKIPA Pharma ROC (Joel Greenblatt) % Related Terms


HOOKIPA Pharma ROC (Joel Greenblatt) % Historical Data

* Premium members only.

The historical data trend for HOOKIPA Pharma's ROC (Joel Greenblatt) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

HOOKIPA Pharma ROC (Joel Greenblatt) % Chart

HOOKIPA Pharma Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
ROC (Joel Greenblatt) %
Get a 7-Day Free Trial -303.07 -414.40 -290.30 -459.75 -610.79

HOOKIPA Pharma Quarterly Data
Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25
ROC (Joel Greenblatt) % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -628.20 -509.28 -1,858.41 -7,052.34 -1,182.78

HOOK vs COCP, LNAI, CYCN: ROC (Joel Greenblatt) % Comparison

For the Biotechnology subindustry, HOOKIPA Pharma's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


HOOKIPA Pharma ROC (Joel Greenblatt) % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, HOOKIPA Pharma's ROC (Joel Greenblatt) % distribution charts can be found below:

* The bar in red indicates where HOOKIPA Pharma's ROC (Joel Greenblatt) % falls into.


HOOK
50GF Score
HOOKIPA Pharma Inc HOOK
ROC (Joel Greenblatt) % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

HOOKIPA Pharma ROC (Joel Greenblatt) % Calculation

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:

ROC (Joel Greenblatt) %=EBIT/Average of (Net fixed Assets + Net Working Capital)

EBIT stands for Earnings Before Interest and Taxes.

Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.

GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.

Working Capital(Q: Mar. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0.545 + 0 + 11.508) - (12.692 + 3.633 + 0)
=-4.272

Working Capital(Q: Jun. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0.903 + 0 + 7.942) - (12.91 + 0 + 0.0010000000000012)
=-4.066

When net working capital is negative, 0 is used.

So ROC (Joel Greenblatt) % of HOOKIPA Pharma for the quarter that ended in Jun. 2025 can be restated as:

ROC (Joel Greenblatt) %(Q: Jun. 2025 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Mar. 2025  Q: Jun. 2025
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-7.144/( ( (0.686 + max(-4.272, 0)) + (0.522 + max(-4.066, 0)) )/ 2 )
=-7.144/( ( 0.686 + 0.522 )/ 2 )
=-7.144/0.604
=-1,182.78 %

Note: The EBIT data used here is four times the quarterly (Jun. 2025) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a ROC (Joel Greenblatt) % of -1,182.78% mean?
HOOKIPA Pharma (HOOK) has a ROC (Joel Greenblatt) % of -1,182.78% as of Jun. 2025. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on HOOKIPA Pharma and its competitors. According to the industry distribution chart, HOOKIPA Pharma ranks #916 out of 1321 companies in the Biotechnology industry, placing it in the top 69.3%.
Is HOOKIPA Pharma's ROC (Joel Greenblatt) % too high?
HOOKIPA Pharma's current ROC (Joel Greenblatt) % is -1,182.78%. Based on the distribution chart, HOOKIPA Pharma ranks #916 out of 1321 companies in the Biotechnology industry, which is below the industry midpoint. Overall, HOOKIPA Pharma has a GF Score™ of 50/100, reflecting its overall financial health beyond just this single metric.
How does HOOKIPA Pharma's ROC (Joel Greenblatt) % compare to COCP and LNAI?
According to the Biotechnology industry distribution chart, HOOKIPA Pharma ranks #916 out of 1321 companies for ROC (Joel Greenblatt) %. This places HOOKIPA Pharma in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC (Joel Greenblatt) % for a Biotechnology company?
A good ROC (Joel Greenblatt) % depends on the Biotechnology industry context. However, ROC (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC (Joel Greenblatt) % mean?
A high ROC (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on HOOKIPA Pharma and its competitors. HOOKIPA Pharma's current ROC (Joel Greenblatt) % is -1,182.78%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is HOOKIPA Pharma stock overvalued right now?
HOOKIPA Pharma (HOOK) has a current ROC (Joel Greenblatt) % of -1,182.78%. The current ROC (Joel Greenblatt) % is -1,182.78%. HOOKIPA Pharma's overall GF Score™ is 50/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC (Joel Greenblatt) % calculated?
ROC (Joel Greenblatt) % is calculated from a company's financial statements. For HOOKIPA Pharma (HOOK), the current ROC (Joel Greenblatt) % is -1,182.78% as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

HOOKIPA Pharma Business Description

Address 350 Fifth Avenue, 72nd Floor, Suite 7240, New York, NY, USA, 10118
HOOKIPA Pharma Inc is a clinical-stage biopharmaceutical company developing a class of immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform that is designed to reprogram the body's immune system. The company's product candidates are designed to induce specific, robust and durable CD8+ T cells and antibodies to eliminate cancers and serious infectious diseases. Its pipeline includes biological therapies for oncology, targeting human papillomavirus type 16-positive (HPV16+) cancers, KRAS mutated cancers, and other targets. In addition, It is also focused to develop therapies that are intended to provide functional cures for hepatitis B virus (HBV) and human immunodeficiency virus-1 (HIV-1).
50GF Score

Get the complete analysis for HOOK

ROC (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.15
Price